Target intelligence / Profile preview

Multiple surface antigen on Neisseria meningitidis outer membrane vesicle

Molecular classification
Other (bacterial outer membrane proteins, porins, adhesins, lipoproteins, LPS, and various outer membrane components)
01

Overview

Multiple surface antigens on Neisseria meningitidis outer membrane vesicle" refers to the heterogeneous group of exposed proteins, lipoproteins, and lipopolysaccharides present on the surface of outer membrane vesicles (OMVs) naturally shed by Neisseria meningitidis. OMVs are spherical lipid bilayer particles (20–300 nm) structurally resembling the outer membrane of the bacterium, including major surface proteins such as porins (PorA, PorB), adhesion molecules (e.g., Opa, Opc), iron transporters (e.g., FetA), and immunologically active lipopolysaccharides (LPS), among others[2][3][5][6]. These vesicles play roles in bacterial pathogenesis (adhesion, immune evasion, modulation)[1][3], but are best known as the basis for meningococcal group B vaccines where their mixture of surface antigens elicits strain-specific protective immunity[5][6]. As a vaccine component, OMV antigen selection and purification is critical to ensure efficacy while minimizing reactogenicity (toxicity from LPS)[2]. The "target" is not any single purified molecule, but rather a complex mixture; for structured annotation, individual components (such as PorA, PorB, Opa) may need to be treated as distinct canonical antigens.

Other names
Neisseria meningitidis OMV antigensOuter membrane vesicle (OMV) surface antigens from Neisseria meningitidisMeningococcal OMV surface proteins
02

Mechanism of action

Induction of protective immunity as vaccine antigens Modulation or inhibition of immune cells (e.g., Opa protein binding to CEACAM1 inhibits T cell activation)[1]

03

Biological functions

Immune response modulationAdhesion to host cellsEvasion of host immunityVaccine antigenicity
04

Disease associations

Infection (bacterial meningitis, sepsis)
05

Safety considerations

Endotoxin (lipopolysaccharide, LPS) reactogenicity[2]Strain specificity of immune responsePotential to induce immune suppression in some contexts (e.g., Opa-mediated T cell inhibition)[1]
06

Interacting drugs

None (but see vaccines: Bexsero, MenB vaccines contain OMV antigens)
07

Biomarkers

Presence of bactericidal antibody titers after immunization with OMV-based vaccines[6]

Beyond the preview

Go deeper on Multiple surface antigen on Neisseria meningitidis outer membrane vesicle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multiple surface antigen on Neisseria meningitidis outer membrane vesicle.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call